Study Comparing Venlafaxine vs. Paroxetine in Panic Disorder
Information source: Wyeth
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Panic Disorders
Intervention: VENLAFAXINE (Drug); Paroxetine (Drug)
Phase: Phase 3
Sponsored by: Wyeth
Official(s) and/or principal investigator(s):
Medical Monitor, Study Director, Affiliation: Wyeth
The purpose of this pilot study is to evaluate the improvement in social function following
therapy with venlafaxine extended release (XR) in the treatment of panic disorder (PD) in
comparison to paroxetine. An additional purpose of this pilot study is to obtain the
tolerability of using venlafaxine extended release (XR) in the treatment of panic disorder
(PD) in comparison to paroxetine.
Official title: Pilot Study of Venlafaxine Extended Release (XR) in the Treatment of Panic Disorder (PD) in Comparison to Paroxetine.
Study design: Treatment, Randomized, Open Label, Dose Comparison, Parallel Assignment, Safety/Efficacy Study
Primary outcome: To evaluate the improvement of social function following therapy with Venlafaxine extended release (XR)in the Treatment of Panic Disorder in comparision to Paroxetine.
Secondary outcome: Obtain the tolerability of using Venlafaxine extended release (XR) in the treatment of Panic Disorder in comparision to Paroxetine.
Minimum age: 18 Years.
Maximum age: 65 Years.
- Meet DSM IV criteria for Panic Disorder (with or without agoraphobia) for at least 3
months before study day 1.
- Have a minimum of 8 full-symptom panic attacks during the 4 weeks before the screening
- Provide a written informed consent
- Treatment with Venlafaxine within 6 months of study day 1, as well Paroxetine
- Known hypersensitivity to Venlafaxine or related compounds as well to Paroxetine.
- Psychopharmacologic drugs within 14 days of study day 1
Locations and Contacts
Sao Paulo 04038-031, Brazil
Sao Paulo 04829-000, Brazil
Santo Andre, Sao Paulo 09290-610, Brazil
Jundiai, Sao Paulo, Brazil
Starting date: January 2005
Ending date: April 2006
Last updated: December 18, 2007